Transcranial Magnetic Stimulator (TMS), also referred to us repetitive Transcranial Magnetic Stimulator (rTMS), is a type of brain stimulation in which a changing magnetic field is applied to a specific area of the brain. An electric pulse stimulator is attached to a magnetic coil, which is then connected to the scalp. It is a non-invasive procedure and is used for diagnostic and therapeutic applications.
BrainsWay Ltd and Neuronetics – Notable Market Players in Transcranial Magnetic Stimulator (TMS) Market
Market leaders operating in the market have undertaken various organic growth strategies in the Transcranial Magnetic Stimulator (TMS) market. The Transcranial Magnetic Stimulator (TMS) market majorly consists of the players BrainsWay Ltd, Nexstim, Magstim, Neuronetics, TMS Neuro Solutions, MagVenture, Inc., eNeura Inc., Neurosoft, MAG & More GmbH. REMED are among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the Transcranial Magnetic Stimulator (TMS) market:
| Year | News |
| Mar-21 | MagVenture introduced the MagVenture Flow Arm — a patent pending, clinical positioning system to optimize the delivery of MagVenture’s FDA cleared protocols for non-invasive brain stimulation technology within the treatment of major depressive disorder and as an adjunct therapy for OCD. |
| Aug-20 | FDA has cleared MagVenture TMS Therapy for adjunct treatment of Obsessive-Compulsive Disorder (OCD). This marks the second indication in the US for the Danish medical device company MagVenture who is already FDA cleared for the treatment of major depressive disorder |
| Aug-20 | BrainsWay Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s deep Transcranial Magnetic Stimulator (Deep TMS) system for its use as an aid in short-term smoking cessation in adults. |
| Jan-19 | Neuronetics, Inc has partnered with Success TMS. This partnership is likely to Increase Patient Access to Leading Depression Treatment, NeuroStar Advanced Therapy |
